Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.

Zhou PR, Liu HJ, Liao EY, Zhang ZL, Chen DC, Liu J, Wu W, Xing XP, Xia WB, Xu L, Li M.

Pharmacogenomics. 2014 Apr;15(6):821-31. doi: 10.2217/pgs.14.12.

PMID:
24897288
2.

SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.

Zhou PR, Xu XJ, Zhang ZL, Liao EY, Chen DC, Liu J, Wu W, Jiang Y, Wang O, Xia WB, Xing XP, Xu L, Li M.

Pharmacogenomics. 2015;16(10):1077-88. doi: 10.2217/pgs.15.76.

3.

Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.

Liu Y, Liu H, Li M, Zhou P, Xing X, Xia W, Zhang Z, Liao E, Chen D, Liu J, Tao T, Wu W, Xu L.

Chin Med J (Engl). 2014;127(4):662-8.

4.

LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.

Kruk M, Ralston SH, Albagha OM.

Calcif Tissue Int. 2009 Mar;84(3):171-9. doi: 10.1007/s00223-008-9207-5.

PMID:
19148563
5.

Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.

Wang C, Zheng H, He JW, Zhang H, Yue H, Hu WW, Gu JM, Shao C, Fu WZ, Hu YQ, Li M, Liu YJ, Zhang ZL.

Pharmacogenomics J. 2015 Apr;15(2):158-64. doi: 10.1038/tpj.2014.52.

PMID:
25223561
6.

Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women.

Markatseli AE, Hatzi E, Bouba I, Georgiou I, Challa A, Tigas S, Tsatsoulis A.

Maturitas. 2011 Oct;70(2):188-93. doi: 10.1016/j.maturitas.2011.07.016.

PMID:
21840657
7.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
8.

Polymorphism of LRP5, but not of TNFRSF11B, is associated with a decrease in bone mineral density in postmenopausal Maya-Mestizo women.

Canto-Cetina T, Polanco Reyes L, González Herrera L, Rojano-Mejía D, Coral-Vázquez RM, Coronel A, Canto P.

Am J Hum Biol. 2013 Nov-Dec;25(6):713-8. doi: 10.1002/ajhb.22464.

PMID:
24130145
9.

OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.

Zheng H, Wang C, He JW, Fu WZ, Zhang ZL.

Pharmacogenet Genomics. 2016 Jan;26(1):12-9. doi: 10.1097/FPC.0000000000000181.

PMID:
26426211
10.

Impact of genetic variants of IL-6, IL6R, LRP5, ESR1 and SP7 genes on bone mineral density in postmenopausal Mexican-Mestizo women with obesity.

Méndez JP, Rojano-Mejía D, Coral-Vázquez RM, Coronel A, Pedraza J, Casas MJ, Soriano R, García-García E, Vilchis F, Canto P.

Gene. 2013 Oct 10;528(2):216-20. doi: 10.1016/j.gene.2013.07.008.

PMID:
23891823
11.

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.

Bone. 2010 Apr;46(4):935-9. doi: 10.1016/j.bone.2009.12.032.

PMID:
20060081
12.

Association of LRP5 genotypes with osteoporosis in Tunisian post-menopausal women.

Sassi R, Sahli H, Souissi C, El Mahmoudi H, Zouari B, Ben Ammar ElGaaied A, Sellami S, Ferrari SL.

BMC Musculoskelet Disord. 2014 Apr 30;15:144. doi: 10.1186/1471-2474-15-144.

13.

The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.

J Bone Miner Metab. 2009;27(4):471-8. doi: 10.1007/s00774-009-0057-7.

PMID:
19343272
14.

The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women.

Wang JY, Zhou PR, Liu Y, Xu XJ, Ma DD, Xia WB, Jiang Y, Wang O, Xing XP, Li M.

Pharmacogenomics. 2016 Feb;17(3):209-17. doi: 10.2217/pgs.15.167.

PMID:
26780085
15.
16.

Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis.

Tran BN, Nguyen ND, Eisman JA, Nguyen TV.

BMC Med Genet. 2008 Jun 27;9:55. doi: 10.1186/1471-2350-9-55.

17.

[Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].

Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X.

Zhonghua Yi Xue Za Zhi. 2002 Sep 25;82(18):1254-6. Chinese.

PMID:
12425805
18.

Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women.

Han LW, Ma DD, Xu XJ, Lü F, Liu Y, Xia WB, Jiang Y, Wang O, Xing XP, Li M.

Chin Med Sci J. 2016 Mar 20;31(1):8-16.

PMID:
28031082
19.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.

J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.

20.

Association of estrogen receptor alpha and collagen type I alpha 1 gene polymorphisms with bone mineral density in postmenopausal women.

Erdogan MO, Yıldız H, Artan S, Solak M, Taşcıoğlu F, Dündar U, Eser B, Colak E.

Osteoporos Int. 2011 Apr;22(4):1219-25. doi: 10.1007/s00198-010-1312-4.

PMID:
20532479
Items per page

Supplemental Content

Support Center